Vimarsana
Biggest News Aggregation in the World

Key Clinical Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Key Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Key Clinical Program Today - Breaking & Trending Today

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones - Vimarsana News

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

Published: January 3, 2024

- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected...

Source: marketscreener.com
Related Topics:
Megan McgrathIvana MagovLeah GibsonKey Clinical ProgramEuropean CommissionVigil Neuroscience IncInvestor Relations Corporate CommunicationsDrug AdministrationExchange CommissionHealthcare ConferenceChief Executive OfficerClinical Program HighlightsInvestigational New DrugCorporate HighlightsVigil NeuroscienceQuarterly ReportInvestor RelationsCorporate Communications
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates - Vimarsana News

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Published: August 17, 2023

Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐...

Source: prnewswire.com
Related Topics:
United StatesSouth KoreaKalbe Genexine BiologicsGivastomig ClaudinTyler EhlerRaj KannanGigi FengBiopharma Hangzhou Co LtdBoard Of Directors The CompanyEuropean Society Of Medical OncologyCorporate DevelopmentAbbvie IncKey Clinical ProgramResearch Development ExpensesExchange CommissionExchange Rate InformationHuman Immunology Biosciences IncCompany Board Of DirectorsTracon Pharmaceuticals IncTopline PhaseChief Executive OfficerClinical ProgramEuropean SocietyMedical OncologyMyeloma Results Expected